Pieris Pharmaceuticals Inc (PIRS)
16.26
+0.33
(+2.05%)
USD |
NASDAQ |
Nov 22, 10:48
Pieris Pharmaceuticals Enterprise Value: 1.673M for Nov. 21, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 21, 2024 | 1.673M |
| November 20, 2024 | 1.773M |
| November 19, 2024 | 1.219M |
| November 18, 2024 | 1.021M |
| November 15, 2024 | 1.586M |
| November 14, 2024 | 1.694M |
| November 13, 2024 | 1.892M |
| November 12, 2024 | 1.919M |
| November 11, 2024 | 1.721M |
| November 08, 2024 | 2.923M |
| November 07, 2024 | 2.460M |
| November 06, 2024 | 2.758M |
| November 05, 2024 | 3.148M |
| November 04, 2024 | 3.125M |
| November 01, 2024 | 3.546M |
| October 31, 2024 | 3.410M |
| October 30, 2024 | 2.909M |
| October 29, 2024 | 3.080M |
| October 28, 2024 | 3.080M |
| October 25, 2024 | 2.998M |
| October 24, 2024 | 3.080M |
| October 23, 2024 | 3.014M |
| October 22, 2024 | 2.319M |
| October 21, 2024 | 2.816M |
| October 18, 2024 | 2.974M |
| Date | Value |
|---|---|
| October 17, 2024 | 2.988M |
| October 16, 2024 | 2.407M |
| October 15, 2024 | 2.090M |
| October 14, 2024 | 2.118M |
| October 11, 2024 | 2.486M |
| October 10, 2024 | 2.222M |
| October 09, 2024 | 1.985M |
| October 08, 2024 | 1.815M |
| October 07, 2024 | 1.998M |
| October 04, 2024 | 2.104M |
| October 03, 2024 | 2.143M |
| October 02, 2024 | 2.486M |
| October 01, 2024 | 2.566M |
| September 30, 2024 | 2.526M |
| September 27, 2024 | 1.603M |
| September 26, 2024 | 1.603M |
| September 25, 2024 | 2.039M |
| September 24, 2024 | 2.805M |
| September 23, 2024 | 2.976M |
| September 20, 2024 | 3.029M |
| September 19, 2024 | 2.699M |
| September 18, 2024 | 1.603M |
| September 17, 2024 | 2.132M |
| September 16, 2024 | 2.184M |
| September 13, 2024 | 2.277M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-38.52M
Minimum
Jun 30 2023
271.17M
Maximum
Sep 17 2021
53.20M
Average
47.76M
Median
Enterprise Value Benchmarks
| Ligand Pharmaceuticals Inc | 1.983B |
| NovaBay Pharmaceuticals Inc | 2.798M |
| Palatin Technologies Inc | 15.96M |
| iBio Inc | 12.31M |
| Theriva Biologics Inc | -12.68M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -2.887M |
| Total Expenses (Quarterly) | 3.135M |
| EPS Diluted (Quarterly) | -2.19 |
| Earnings Yield | -74.85% |
| Normalized Earnings Yield | -6.422 |